ASH: Daratumumab Beneficial for Patients With Multiple Myeloma

WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news